Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

NCT00770536 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00770536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00770536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2009
Completion date
June 30, 2015
Enrollment
103 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, carcinoma, fallopian tube cancer, gynecological malignancies, metastases, oncology, ovarian cancer, solid tumors, tumors